Table II.
Survival outcomes of patients with aggressive non-Hodgkin lymphomas, stratified by histology and time from diagnosis to start of chemotherapy.
| Lymphoma, time to treatment | 3-year OS | Models stratified by IPI a | Multivariable models b | |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| % | 95% CI | N | HR | 95% CI | N | HR | 95% CI | |
| DLBCL | ||||||||
|
| ||||||||
| 0–7 days | 56.1 | (55.2–56.9) | 2,590 | 1.38 | (1.28–1.48) | 15,728 | 1.66 | (1.61–1.71) |
|
| ||||||||
| 8–14 days | 61.3 | (60.5–62.0) | 3,303 | 1.17 | (1.08–1.25) | 18,903 | 1.44 | (1.40–1.48) |
|
| ||||||||
| 15–30 days | 70.2 | (69.7–70.7) | 6,674 | 1.05 | (0.99–1.12) | 35,744 | 1.13 | (1.10–1.16) |
|
| ||||||||
| >30 days | 74.4 | (73.9–74.9) | 5,703 | Ref. | 34,090 | Ref. | ||
|
| ||||||||
| BL | ||||||||
|
| ||||||||
| 0–7 days | 56.5 | (53.9–59.1) | 1,502 | 1.42 | (1.22–1.66) | 1,502 | 1.51 | (1.29–1.77) |
|
| ||||||||
| 8–14 days | 62.3 | (59.3–65.1) | 1,131 | 1.24 | (1.06–1.46) | 1,131 | 1.29 | (1.09–1.52) |
|
| ||||||||
| 15–30 days | 67.4 | (64.6–70.0) | 1,237 | 1.11 | (0.94–1.30) | 1,237 | 1.15 | (0.97–1.35) |
|
| ||||||||
| >30 days | 70.5 | (66.8–73.8) | 682 | Ref. | 682 | Ref. | ||
|
| ||||||||
| MCL | ||||||||
|
| ||||||||
| 0–7 days | 44.8 | (42.1–47.6) | 177 | 2.23 | (1.79–2.78) | 1,431 | 2.26 | (2.08–2.46) |
|
| ||||||||
| 8–14 days | 55.2 | (52.5–57.7) | 237 | 1.56 | (1.27–1.93) | 1,578 | 1.73 | (1.59–1.88) |
|
| ||||||||
| 15–30 days | 65.4 | (63.7–67.0) | 501 | 1.18 | (0.99–1.41) | 3,602 | 1.27 | (1.18–1.36) |
|
| ||||||||
| >30 days | 74.6 | (73.2–75.8) | 723 | Ref. | 5,112 | Ref. | ||
|
| ||||||||
| PTCL | ||||||||
|
| ||||||||
| 0–7 days | 37.2 | (34.6–39.9) | 216 | 1.46 | (1.18–1.81) | 1,402 | 1.70 | (1.57–1.85) |
|
| ||||||||
| 8–14 days | 44.0 | (41.7–46.4) | 251 | 1.28 | (1.04–1.58) | 1,826 | 1.40 | (1.30–1.52) |
|
| ||||||||
| 15–30 days | 48.5 | (46.7–50.4) | 500 | 1.28 | (1.07–1.52) | 3,130 | 1.24 | (1.16–1.33) |
|
| ||||||||
| >30 days | 54.6 | (52.8–56.3) | 551 | Ref. | 3,451 | Ref. | ||
a
IPI for DLBCL, MCL, and PTCL population-based prognostic index for Burkitt lymphoma(Castillo et al, 2013)
b
Model adjusting for age, sex, race/ethnicity, stage, presence of B-symptoms, primary site, comorbidity index, and median income in the county of residence (Olszewski et al, 2015)
BL: Burkitt lymphoma; CI: confidence interval; DLBCL: diffuse large B-cell lymphoma; HR: hazard ratio; IPI: international prognostic index; MCL: mantle cell lymphoma; OS: overall survival; PTCL: peripheral T-cell lymphoma; Ref.: reference level.